DNA Sep 2024 0.500 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0500 |
| Ask | 0.1000 |
| Strike | 0.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 0.0200 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 6.45k |
PR NewswireSyngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology.
ZacksAfter Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Simply Wall St.Should Shareholders Have Second Thoughts About A Pay Rise For Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) CEO This Year?
Key Insights Ginkgo Bioworks Holdings' Annual General Meeting to take place on 13th of June Salary of US$250.0k is part...
